Health and wellness company Herbalife has reached an agreement to acquire assets from Bioniq. This UK-based personalized supplements company focuses on making health more accessible and actionable.
The transaction will complement Herbalife’s 2025 acquisitions of Pro2col, a digital health and wellness application company, and Link BioSciences, a company processing biometrics, biomarkers, lifestyle data, DNA, and data from Pro2col to formulate customized nutritional supplements.
Herbalife says these acquisitions enable it to offer a broader range of personalized supplements in multiple delivery formats.
“The future of health and wellness is becoming more personalized and informed by data,” says Stephan Gratziani, Herbalife CEO. “By combining Bioniq’s personalized supplement technology with Pro2col and the power of our global distributor network, we are expanding our ability to deliver personalized wellness at a global scale.”
The transaction is expected to close in Q2 of 2026, subject to customary closing conditions and regulatory approvals. The US$55 million purchase price will be paid over five years, including an initial payment of US$10 million at closing.
Moreover, Herbalife notes that the transaction value includes up to US$95 million of contingent payments based on future performance.
The company expects to offer Bioniq’s personalized supplements to customers through its distributors in the US and select countries in Europe later this year.
Data-driven health
Herbalife says the acquisition advances the company’s vision to become a technology-enabled, data-driven health and wellness platform.
Bioniq develops personalized supplement formulas by combining its patented product personalization framework, a person’s health background, and its proprietary database of biomarkers. The resulting formulations are designed for a wide range of individuals, from everyday wellness consumers to elite athletes.
“I founded Bioniq in 2019 with a vision to help people optimize their well-being through a science-driven approach to nutrition that incorporates biomarker and lifestyle data,” says Vadim Fedotov, founder and president of Bioniq. “I am excited to join Herbalife with its global distributor network and commitment to advancing wellness at scale.”
Bioniq develops personalized formulas based on a product personalization engine, personal background, and biomarker database (Image credit: Bioniq).Herbalife has also obtained a call option to acquire Bioniz LAB, a platform focusing on small molecules and peptides. This option enables the company to evaluate potential longer-term opportunities in this area.
Portuguese footballer Cristiano Ronaldo, a nutrition partner of Herbalife and shareholder in Bioniq, says he shares the company’s vision to improve access to personalized supplements at scale through Herbalife’s global distributor network.
“Throughout my career, biometrics and personalized nutrition have been central to helping me perform and compete at the highest level,” says Ronaldo. “I’ve experienced firsthand how a tailored approach to nutrition can help optimize performance.”
“I’m delighted to see Bioniq’s personalized supplements become part of Herbalife’s expanding access to nutritional supplements, helping people take a more informed approach to their health, wellness, and performance.”
Mergers & acquisitions news
Herbalife’s acquisition of Bioniq follows a wave of acquisitions in the food and nutrition space to expand companies’ portfolios.
Last week, Danone entered into a definitive agreement to acquire Huel, which offers complete, nutritionally balanced meal solutions. With this acquisition, Danone aims to expand its functional nutrition portfolio.
Earlier this year, Lone Star Funds announced it would acquire the Capsules & Health Ingredients division under the Lonza Group as a standalone business with greater flexibility.
Moreover, Darling Ingredients and Tessenderlo Group combined the collagen and gelatin segments of their companies, Rousselot and PB Leiner, into a new, collagen-based nutrition company. The new company has an expected revenue of US$1.5 billion, with the deal expected to close this year.
